Shared by
beno
Fundamentals
N/a
Catalysts / News / Painting the picture
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
Technical Analysis
-Daily chart shows many signs of dilution (upside wicks, price closing weak when volume present)
-Price pumped $1 in PM
-Backside right off the open, clear downtrend, below VWAP all day
-Levels: 2.40, 2.60, 3
Original Plan / Strategy
Trade 1: First Test short of 2.40 zone
Trade 2: First Test short of 2.25 zone
Review
Trades were good, first was successful, second was a scratch.
Execution detail:
| Date/time | Symbol | Side | Price | Position |
|---|---|---|---|---|
| 2019-12-02 09:44:39 | AKTX | sell | $2.390 | short |
| 2019-12-02 09:46:53 | AKTX | buy | $2.270 | 0 |
| 2019-12-02 10:05:38 | AKTX | sell | $2.240 | short |
| 2019-12-02 10:11:23 | AKTX | buy | $2.250 | 0 |
Leave a comment about this trade!
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!